Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Jonas Hannestad, MD, PhD, chief medical officer at Gain Therapeutics, provided clinical perspective on promising data from a phase 1 first-in-human study of GT-02287, an investigational therapy for Parkinson disease with or without a GBA1 mutation.

Understanding the Therapeutic Potential of GT-02287 in GBA-Parkinson Disease

Over an 18-month period, patients showed strengthened scores on Rasch-built Overall Disability Scale, a patient-reported outcome measure of activity and social participation.

Vutrisiran Treatment Leads to Quality of Life Enhancements in hATTR-Polyneuropathy

Videos

Beyond the Guidelines: Monitoring and Defining SMA Progression

Here's some of what is coming soon to NeurologyLive® this week. 

This Week on NeurologyLive® — October 14, 2024

, has been with the team since October 2019. Follow him on Twitter 

In this segment, the panel discussed adult-onset 5q spinal muscular atrophy (SMA), highlighting its frequent underdiagnosis and subtle symptoms such as cramps, fasciculations, and sports intolerance.

Adult-Onset SMA: Diagnosis and Best Practices for Clinicians

The discussion highlighted the need for national or local protocols, insurance approvals, and close collaboration with families to optimize patient outcomes.

Optimizing Treatment Access in SMA: Navigating Timing and Outcomes

Pharmacist and Director of Clinical Content and Resources on the Clinical Innovation and Strategy team at the National Multiple Sclerosis Society

Sarah Anderson, PharmD, NBC-HWC, senior director of clinical resources and programming at National MS Society, talked about the significant updates under the Inflation Reduction Act to come in 2025 for patients with multiple sclerosis. 

Key Takeaways for MS Providers Regarding Major Medicare Changes Expected in 2025

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

ECTRIMS 2024

MDS 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

We present a selection of interesting neurology articles for the month of May in the following slides. See the slide legends for links to the article summaries.

Slideshows

May news includes ground-breaking FDA approvals, predictions of Alzheimer disease, and a possible biomarker for mild traumatic brain injury.

Clinical

BIO-22-NRD0187 - /clinical/headache-migraine

EMD-22-NRD0193 - /clinical/multiple-sclerosis

Interesting Neuro: Stroke Warning & Cluster Headache